CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Opthea Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Opthea Ltd
Suite 0403
Level 4, 650 Chapel Street, South Yarra
Phone: +61 398260399p:+61 398260399 MELBOURNE, VIC  3141  Australia Ticker: OPTOPT

Business Summary
Opthea Limited is an Australia-based biotechnology company. The Company is engaged in the development and commercialization of therapies primarily for eye disease. The Company’s lead asset, OPT-302, is a novel biologic inhibitor of VEGF-C and VEGF-D, for use in combination with VEGF-A inhibitors for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The Company’s principal activities include the progression of the Company’s Phase III registration trials of OPT-302 for wet AMD. It also manufactures OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. The Company’s development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/20236/30/2023YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Independent Chairman of the Board Jeremy M.Levin 70 10/12/2020 10/12/2020
Chief Executive Officer FredericGuerard 50 10/27/2023 10/27/2023
Chief Financial Officer Peter F.Lang 51 10/27/2023 10/27/2023
12 additional Officers and Directors records available in full report.

Business Names
Business Name
Circadian Technologies Limited
CKDXY
OPT
Opthea US Inc.
Vegenics Pty Ltd.

General Information
Number of Employees: 5 (As of 6/30/2005)
Outstanding Shares: 662,808,634 (As of 12/31/2023)
Shareholders: 7,448
Stock Exchange: ASX
Fax Number: +61 398240083


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024